(thirdQuint)A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia.

 This study will enroll adult subjects (greater than or equal to 18 years of age) with type 2 diabetes mellitus and elevated LDL-C or non-HDL-C levels on a stable, maximally tolerated statin dose of at least moderate-intensity at signing of the informed consent; statin therapy must remain unchanged during screening and the remainder of the study.

 Subjects must have hemoglobin A1c (HbA1c) < 10%, must have been receiving pharmacologic treatment for diabetes mellitus for greater than or equal to 6 months prior to screening, with stable diabetes therapy prior to randomization to investigational product (IP) and not expected to change throughout the duration of study participation.

.

 A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia@highlight

The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in subjects with type 2 diabetes mellitus and high blood cholesterol on a maximally tolerated oral dose of statin of at least moderate-intensity.

